Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

NCT01766258 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: ODM-101 65mg Carbidopa
DRUG: ODM-101 105mg Carbidopa
DRUG: Stalevo

Sponsor

Orion Corporation, Orion Pharma